Table 2.
Summary of results, with hazard ratios and P values calculated for overall survival from start of bevacizumab therapy
| Median (range) | HRc (95% CI) | P Value | |
|---|---|---|---|
| Age | 0.983 (0.959–1.008) | .19 | |
| KPS (<80 vs ≥80) | – | 1.159 (0.571–2.354) | .68 |
| First vs later progression | – | 1.077 (0.528–2.197) | .84 |
| Low-ADC lesion present before beginning bevacizumab | – | 1.160 (0.663–2.030) | .60 |
| Pre-bevacizumab scan | |||
| Nonenhancing volume, cm3 | 120.71 (14.36–412.04) | 1.004 (1.000–1.008) | .025d |
| Enhancing volume, cm3 | 29.61 (1.76–87.59) | 1.007 (0.996–1.020) | .22 |
| Low-ADC volume, cm3 | 12.82 (0.70–167.39) | 0.998 (0.987–1.009) | .73 |
| Normalized 5th percentile low-ADC | 1.018 (0.510–1.633) | 1.112 (0.242–5.119) | .89 |
| First post-bevacizumab scana | |||
| Nonenhancing volume, cm3 | 64.18 (5.90–269.88) | 1.001 (0.996–1.007) | .60 |
| Δ Nonenhancing volume | −48.7% (−94.1–475.0) | 1.000 (0.995–1.006) | .95 |
| Enhancing volume, cm3 | 13.58 (0.07–85.88) | 1.015 (1.001–1.029) | .040d |
| Δ Enhancing volume | −46.8% (−99.5–305.4) | 1.004 (0.999–1.009) | .11 |
| Low-ADC volume, cm3 | 15.20 (0.41–146.07) | 1.010 (0.999–1.020) | .36 |
| Δ Low-ADC volume | −7.0% (−79.7–406.9) | 1.000 (0.999–1.004) | .37 |
| Normalized 5th percentile low-ADC | 0.884 (0.452–1.246) | 1.066 (0.171–6.635) | .95 |
| Δ Normalized 5th percentile low-ADC | −13.2% (−44.4–108.5) | 1.002 (0.988–1.016) | .78 |
| 2nd post-bevacizumab scanb | |||
| Nonenhancing volume, cm3 | 53.14 (2.72–490.49) | 1.004 (0.999–1.008) | .11 |
| Δ Nonenhancing volume | −0.6% (−95.2–188.4) | 1.006 (0.998–1.013) | .12 |
| Enhancing volume, cm3 | 10.47 (0.01–120.89) | 1.017 (1.005–1.028) | .004d |
| Δ Enhancing volume | −10.0% (−93.6–1,193.6) | 1.000 (0.999–1.002) | .74 |
| Low-ADC volume, cm3 | 12.94 (0.66–263.87) | 1.014 (1.003–1.025) | .009d |
| Δ Low-ADC volume | 6.8% (−95.2–1,116.8) | 1.001 (0.999–1.002) | .26 |
| Normalized 5th percentile low-ADC | 0.904 (0.020–1.925) | 0.57 (0.11–3.06) | .52 |
| Δ Normalized 5th percentile low-ADC | 1.6% (−98.2–178.3) | 1.000 (0.999–1.010) | .71 |
Abbreviations: ADC, apparent diffusion coefficient; CI, confidence interval; HR, hazard ratio.
aΔ calculated from pre-bevacizumab.
bΔ calculated from first post-bevacizumab.
cHR per 1 cm3 increase from the median 13 cm3.
dStatistically significant.